Detalles de la búsqueda
1.
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function.
Cell
; 185(4): 585-602.e29, 2022 02 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35051368
2.
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
BJU Int
; 2024 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38456541
3.
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Int J Mol Sci
; 25(7)2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38612799
4.
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients.
Cancer Immunol Immunother
; 72(7): 1991-2001, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37017694
5.
[Tumour immunotherapy - mechanism and side effects].
Ther Umsch
; 80(8): 359-362, 2023 Oct.
Artículo
en Alemán
| MEDLINE | ID: mdl-37971526
6.
Tumour neoantigen mimicry by microbial species in cancer immunotherapy.
Br J Cancer
; 125(3): 313-323, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33824481
7.
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Cancer Immunol Immunother
; 70(5): 1255-1262, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33130956
8.
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
J Pathol
; 250(1): 19-29, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31471895
9.
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
Cancer Immunol Immunother
; 69(8): 1605-1613, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32307579
10.
Oncologist recommendation matters!-Predictors of psycho-oncological service uptake in oncology outpatients.
Psychooncology
; 28(2): 351-357, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30466146
11.
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immunerelated adverse events among cancer patients.
Cancer Immunol Immunother
; 72(7): 2003-2004, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154850
12.
SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics.
BMC Med Inform Decis Mak
; 18(1): 89, 2018 10 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373609
13.
Understanding why cancer patients accept or turn down psycho-oncological support: a prospective observational study including patients' and clinicians' perspectives on communication about distress.
BMC Cancer
; 17(1): 385, 2017 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-28558713
14.
Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells.
Cancer Immunol Immunother
; 65(1): 1-11, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26541588
15.
Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology.
Future Oncol
; 10(2): 211-7, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24490607
16.
Onkologie Moderne Diagnostik und Therapie.
Ther Umsch
; 76(4): 165, 2019 09.
Artículo
en Alemán
| MEDLINE | ID: mdl-31498039
17.
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Eur J Cancer
; 200: 113600, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38330766
18.
Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study.
JTO Clin Res Rep
; 4(5): 100509, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37168879
19.
Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).
BMJ Open
; 13(6): e067634, 2023 06 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286312
20.
Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials.
Eur J Cancer
; 186: 211-221, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37062625